ROPIVACAINE HYDROCHLORIDE INJECTION, USP SOLUTION

Pays: Canada

Langue: anglais

Source: Health Canada

Ingrédients actifs:

ROPIVACAINE HYDROCHLORIDE

Disponible depuis:

FRESENIUS KABI CANADA LTD

Code ATC:

N01BB09

DCI (Dénomination commune internationale):

ROPIVACAINE

Dosage:

10MG

forme pharmaceutique:

SOLUTION

Composition:

ROPIVACAINE HYDROCHLORIDE 10MG

Mode d'administration:

EPIDURAL

Unités en paquet:

15G/50G

Type d'ordonnance:

Ethical

Domaine thérapeutique:

LOCAL ANESTHETICS

Descriptif du produit:

Active ingredient group (AIG) number: 0133273005; AHFS:

Statut de autorisation:

APPROVED

Date de l'autorisation:

2015-03-30

Résumé des caractéristiques du produit

_ _
PRODUCT MONOGRAPH
INCLUDING PATIENT MEDICATION INFORMATION
ROPIVACAINE HYDROCHLORIDE INJECTION, USP
2 mg / mL, 5 mg / mL, and 10 mg / mL
Local Anesthetic
FRESENIUS KABI CANADA LTD.
165 Galaxy Blvd, Suite 100
Toronto, ON M9W 0C8
Date of Revision: September 25, 2023
Submission Control No: 277021
_ _
Ropivacaine Hydrochloride Injection, USP - Product Monograph
Page 2 of 42
_ _
RECENT MAJOR LABEL CHANGES
Not Applicable
TABLE OF CONTENTS
PART I: HEALTH PROFESSIONAL INFORMATION
..........................................................4
1
INDICATIONS
..................................................................................................................4
1.1
Pediatrics
....................................................................................................................4
1.2
Geriatrics
....................................................................................................................4
2
CONTRAINDICATIONS
.................................................................................................4
3
DOSAGE AND ADMINISTRATION
.............................................................................5
3.1
Dosing Considerations
...............................................................................................5
3.2
Recommended Dose and Dosage Adjustment
...........................................................6
4
OVERDOSAGE
.................................................................................................................8
5
DOSAGE FORMS, STRENGTHS, COMPOSITION AND PACKAGING ..............10
6
WARNINGS AND PRECAUTIONS
.............................................................................11
6.1
Special Populations
..................................................................................................16
6.1.1
Pregnant Women
.................................................................................................16
6.1.2
Breast-feeding
......................................................................................